Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Dasatinib leiomyosarcoma not applicable detail...
Unknown unknown BEZ235 leiomyosarcoma not applicable detail...
Unknown unknown BEZ235 + Doxorubicin leiomyosarcoma not applicable detail...
Unknown unknown BKM120 + Doxorubicin leiomyosarcoma not applicable detail...
Unknown unknown Pazopanib leiomyosarcoma not applicable detail...
Unknown unknown Anlotinib leiomyosarcoma not applicable detail...
FGFR1 positive PD173074 leiomyosarcoma decreased response detail...
FGFR1 positive AZD4547 leiomyosarcoma decreased response detail...
FGFR1 positive BGJ398 leiomyosarcoma decreased response detail...
Unknown unknown Alisertib leiomyosarcoma not applicable detail...
Unknown unknown LY3039478 leiomyosarcoma not applicable detail...
Unknown unknown Regorafenib leiomyosarcoma not applicable detail...
Unknown unknown Pembrolizumab leiomyosarcoma no benefit detail...
Unknown unknown Trabectedin leiomyosarcoma not applicable detail...
Unknown unknown Doxorubicin + Nilotinib leiomyosarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed
NCT01446809 Phase I Doxorubicin + Ifosfamide Pazopanib + Doxorubicin + Ifosfamide Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Unknown status
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Active, not recruiting
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting
NCT02303262 Phase II Gemcitabine + Mocetinostat A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed
NCT02584309 Phase II dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting
NCT02987959 Phase II Sapanisertib Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Recruiting
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting
NCT03074318 Phase Ib/II Avelumab + Trabectedin Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Suspended
NCT03114527 Phase II Ribociclib + Everolimus Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Recruiting
NCT03282344 Phase II NKTR-214 + Nivolumab A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting
NCT03437070 Phase I Doxorubicin + Olaratumab + Trabectidin Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma Recruiting
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Not yet recruiting
NCT03718091 Phase II VX-970 M6620 (VX-970) in Selected Solid Tumors Recruiting
NCT03719430 Phase II APX005M + Doxorubicin + Olaratumab APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Not yet recruiting
NCT03761095 Phase I Dacarbazine + PTC596 A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Not yet recruiting